BioPharm shares pre-clinical data for BPX-01 topical gel

BioPharm X Corp., a specialty pharmaceutical company focused on the dermatology market, recently shared early clinical and pre-clinical data for BPX-01 topical gel at the 2017 American Academy of Dermatology (AAD) Annual Meeting.
The company used the opportunity to show that the topical gel can fight acne in a target area without any side effects.
"The 'Holy Grail' in acne treatment is optimizing both efficacy and tolerability," Dr. Ted Lain, board certified dermatologist and investigator on the BioPharmX Phase 2b study of BPX-01, said in a statement. "What dermatologists desperately need is a product with both a very limited side effect profile and reliable efficacy comparable to that of oral antibiotics."
BioPharmX Senior Director of Preclinical Drug Development Usha Nagavarapu delivered the presentation at the meeting in Orlando, Florida. A research poster was given out at the event as well, titled "Development and Assessment of BPX-01, a Novel Topical Minocycline Gel for Treatment of Acne Vulgaris.”
"The research to date shows that BPX-01 topical gel may effectively and safely deliver minocycline to target areas," Kin Chan, executive vice president of research and technology at BioPharmX, said. "The studies so far offer promise to millions of people who cannot take oral minocycline to treat their acne, including the many individuals who are intolerant of systemic antibiotic treatments."